Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .

NCT00041808 is registered in ClinicalTrials.gov with FeRx as lead sponsor.

NCT NCT00041808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .
Lead sponsor
FeRx
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2001
Completion date
April 30, 2003
Enrollment
20
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, cholangiocarcinoma, colorectal neoplasms, esophageal neoplasms, gastrointestinal neoplasms, liver neoplasms, lung neoplasms, melanoma, metastases, neoplasm, pancreatic neoplasms, sarcoma, stomach neoplasms